LamdaGen and Arisan Therapeutics Receive a $2 Million NIH SBIR Phase II Grant to Develop a Dual Rapid Point-of-Care Test for Acute Dengue and Zika Viral Infections
LamdaGen Corporation and Arisan Therapeutics announced today they will share a $2 million Phase II…